A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 24,100 shares of CLSD stock, worth $24,582. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24,100
Previous 17,600 36.93%
Holding current value
$24,582
Previous $22,000 36.36%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.93 - $1.35 $23,275 - $33,786
-25,027 Reduced 25.9%
71,603 $90,000
Q2 2024

Aug 14, 2024

BUY
$1.08 - $1.58 $28,573 - $41,802
26,457 Added 37.7%
96,630 $125,000
Q1 2024

May 15, 2024

BUY
$1.2 - $2.02 $29,202 - $49,156
24,335 Added 53.09%
70,173 $107,000
Q4 2023

Feb 14, 2024

BUY
$0.68 - $1.18 $17,741 - $30,786
26,090 Added 132.11%
45,838 $53,000
Q3 2023

Nov 14, 2023

BUY
$0.82 - $1.27 $1,956 - $3,030
2,386 Added 13.74%
19,748 $17,000
Q2 2023

Aug 14, 2023

SELL
$0.97 - $1.48 $48,642 - $74,217
-50,147 Reduced 74.28%
17,362 $19,000
Q1 2023

May 15, 2023

BUY
$0.93 - $1.66 $60,383 - $107,780
64,928 Added 2515.61%
67,509 $70,000
Q4 2022

Feb 14, 2023

BUY
$1.0 - $1.5 $2,581 - $3,871
2,581 New
2,581 $2,000
Q2 2022

Aug 15, 2022

SELL
$1.3 - $2.49 $20,634 - $39,523
-15,873 Reduced 50.97%
15,266 $23,000
Q1 2022

May 16, 2022

SELL
$1.35 - $2.88 $10,183 - $21,723
-7,543 Reduced 19.5%
31,139 $71,000
Q4 2021

Feb 14, 2022

SELL
$2.72 - $5.72 $543,989 - $1.14 Million
-199,996 Reduced 83.79%
38,682 $106,000
Q3 2021

Nov 15, 2021

BUY
$4.83 - $7.2 $966,120 - $1.44 Million
200,025 Added 517.49%
238,678 $1.43 Million
Q2 2021

Aug 16, 2021

BUY
$2.32 - $5.38 $31,848 - $73,856
13,728 Added 55.08%
38,653 $188,000
Q1 2021

May 17, 2021

SELL
$2.24 - $4.25 $242,280 - $459,684
-108,161 Reduced 81.27%
24,925 $62,000
Q2 2020

Aug 14, 2020

BUY
$1.55 - $2.41 $104,204 - $162,021
67,229 Added 102.08%
133,086 $250,000
Q1 2020

May 15, 2020

BUY
$1.32 - $3.77 $10,916 - $31,177
8,270 Added 14.36%
65,857 $112,000
Q4 2019

Feb 14, 2020

BUY
$0.62 - $3.4 $2,093 - $11,478
3,376 Added 6.23%
57,587 $167,000
Q2 2019

Aug 14, 2019

BUY
$0.97 - $1.42 $3,968 - $5,809
4,091 Added 8.16%
54,211 $53,000
Q1 2019

May 15, 2019

SELL
$1.1 - $1.74 $15,286 - $24,180
-13,897 Reduced 21.71%
50,120 $0
Q4 2018

Feb 14, 2019

BUY
$1.0 - $6.12 $37,558 - $229,854
37,558 Added 141.95%
64,017 $68,000
Q3 2018

Nov 13, 2018

SELL
$6.03 - $11.24 $282,939 - $527,403
-46,922 Reduced 63.94%
26,459 $0
Q2 2018

Aug 10, 2018

SELL
$8.91 - $14.54 $933,937 - $1.52 Million
-104,819 Reduced 58.82%
73,381 $0
Q1 2018

May 11, 2018

BUY
$5.57 - $14.28 $992,574 - $2.54 Million
178,200 New
178,200 $1.91 Million

Others Institutions Holding CLSD

About Clearside Biomedical, Inc.


  • Ticker CLSD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,190,700
  • Market Cap $61.4M
  • Description
  • Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...
More about CLSD
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.